USPTO Patent Applications - Peptides (C07K)

Polyamine Reporters - Pushkal Sharma, Ankur Jain

The USPTO published patent application US20260109740A1 by inventors Pushkal Sharma and Ankur Jain on April 23, 2026. The application discloses polynucleotides comprising a polyamine-responsive element and a reporter protein coding sequence, where interaction between a polyamine and the polyamine-responsive element modulates expression of the reporter protein. The invention enables methods of reporting and detecting intracellular polyamines and polyamine analogs.

Spirulina Scaffolds for Disease Treatment, Patent Filed

James Michael Roberts, Nhi Yen Khuong, Mesfin Mulugeta Gewe, and Benjamin Jester filed USPTO patent application US20260109742A1 on December 16, 2025 for recombinant Spirulina expressing scaffolds comprising heterologous moieties. The application covers methods of using these scaffolds for the treatment of diseases and conditions, classified under CPC codes C07K 14/47, C12N 15/74, A61K 38/00, and C07K 2319/30.

CD4-Targeted IL-15 Molecules and Methods of Use Patent Application

USPTO published patent application US20260109746A1 for CD4-targeted IL-15 variant molecules and methods of use, filed October 21, 2025 (Application No. 19364662). The application names twelve inventors and covers CPC classifications including C07K 14/5443, A61K 47/6813, and A61P 35/00, indicating therapeutic applications in cancer and antiviral treatments. The application remains in draft stage and has not yet been granted.

US20260109748A1 - Plasmacytoid Dendritic Cell Binding Agents

The USPTO published application US20260109748A1, filed August 13, 2025, disclosing chimeric proteins and protein complexes that bind plasmacytoid dendritic cells (pDC), including Clec4C targets. Invented by Nikolai KLEY, Jan TAVERNIER, Anje CAUWELS, Lennart ZABEAU, and Erik DEPLA, the disclosed agents and pharmaceutical compositions are proposed for diagnostic and therapeutic applications, including treatment of autoimmune diseases. The application has been published for examination but has not yet been granted.

Peptidomimetics for Pancreatic, Colorectal Cancer Diagnostics, Therapeutics

USPTO published application US20260109745A1 on April 23, 2026, covering peptidomimetics targeting the NPC-1 epitope on the MUC5AC protein, which shows differential expression in pancreatic and colorectal cancer. The application, filed October 24, 2025 under Application No. 19367897 with inventor Xue-Ping Wang, also discloses antibodies that selectively bind the NPC-1 epitope for use in diagnostic and therapeutic methods.

STING-Targeting Gene Therapy for SAVI Treatment

The University of Florida Research Foundation has filed a patent application (US20260109741A1) for nucleic acids containing dominant negative STING alleles designed to treat STING-associated vasculopathy with onset in infancy (SAVI), a rare autoimmune condition. The application, filed October 22, 2025, covers both the compositions and methods for delivering these gene therapy constructs to human subjects with STING-mediated diseases. Inventor Lei Jin developed the dominant negative STING allele approach to suppress aberrant STING signaling that drives SAVI pathology.

Novel PYY3-36 Analog Treats Obesity, Diabetes, Depression

The USPTO published patent application US20260109743A1 by inventor Tao Sun disclosing a novel human PYY3-36 analog. The analog demonstrates therapeutic effects across metabolic diseases including obesity, diabetes, and fatty liver, as well as mood disorders such as anxiety and depression. The application was filed on December 16, 2024 under application number 18982094.

IAPP Peptides Inhibit Human Amyloid Polypeptide Aggregation

The USPTO published patent application US20260109744A1 for amyloid peptide variants developed by inventors David Moffet and Luiza Nogaj. The application covers IAPP peptides designed to inhibit aggregation of human Islet Amyloid Polypeptide and their use in preventing amyloid fibril formation. The application was filed on December 17, 2025, under application number 19423936, and received CPC classifications C07K 14/4711, A61P 5/50, and A61K 38/00.

Mixture Of Interferon Alpha 2B With Other Modified Sequences Thereof

PharmaEssentia Corporation filed patent application US20260109749A1 covering a modified interferon alpha 2B composition and associated manufacturing method involving deamidated amino acids. The application, listing six named inventors including Ko-Chung Lin and Ming-Pin Hsu, was published on April 23, 2026 with a filing date of October 17, 2025. The application is assigned number 19361468 and falls under CPC classifications C07K 14/56, C12P 21/02, and A61K 38/00.

IL-2 Protein Conjugate for Cancer Treatment

The USPTO published patent application US20260109747A1 on April 23, 2026, covering an IL-2 protein conjugate comprising an alanine residue (Ala), a cysteine residue (Cys*), and two peptide sequences (SEQ A and SEQ B) with at least 94% sequence identity to SEQ ID NO:1 and SEQ ID NO:2 respectively. The application, filed August 22, 2025 under Application No. 19307745, names inventors Nina Gunnarsson, Matiss Maleckis, and David B. Rosen. CPC classifications include C07K 14/55 (interleukins), A61K 47/542 and A61K 47/60 (protein conjugates for therapeutic use), and A61P 35/00 (antineoplastic agents).

CAREGEN Neutralizing Peptide Against SARS-CoV-2, 2026

CAREGEN CO, LTD. filed US patent application US20260109734A1 on April 23, 2026, for a peptide with neutralizing activity against SARS-CoV-2, with an earlier filing date of October 22, 2025 (Application No. 19365687). The peptide specifically recognizes SARS-CoV-2 proteins, and the application covers three composition types: preventing infection, treating infection, and detecting SARS-CoV-2. Inventors include Yong Ji CHUNG, Eun Mi KIM, Eung Ji LEE, Young Min LEE, Han A KANG, and Min Kyeong JEONG. This published application does not create direct compliance obligations for third parties; entities developing similar therapeutic peptides may wish to review for prior art implications.

In Vivo Protein Immobilization via Self-Crystallization

The USPTO has published patent application US20260109739A1, filed August 14, 2025 (Application No. 19300559), covering a system for in vivo protein immobilization via self-crystallization. Inventors are Michael CHAN, Bradley Heater, and Marianne Lee. The published application claims a novel method for immobilizing recombinantly produced proteins by entrapping them within crystals formed by co-expressed self-crystallizing proteins.

Immunomodulating Polynucleotides, Antibody Conjugates, Methods of Use

US Patent Application US20260109728A1, published April 23, 2026 with a filing date of May 28, 2025, discloses immunomodulating polynucleotides containing 5-modified uridine or cytidine residues, a total of 6 to 16 nucleotides, and abasic spacers or internucleoside phosphotriesters. The application also covers conjugates linking these polynucleotides to targeting moieties, pharmaceutical compositions containing stereochemically enriched internucleoside phosphorothioates, and methods of therapeutic use. Eleven inventors are named including Sukumar SAKAMURI, Curt W. BRADSHAW, and Joseph STOCK.

Multi-Scale Interactome Profiling of Membrane Proteins Using Photocatalytic Proximity Labeling

The USPTO published patent application US20260109733A1, filed on December 9, 2025 (Application No. 19413455), covering photocatalysts for activating multiple photoreactive probes and methods of proximity labeling proteins on a cell surface. The application was submitted by inventors James Wells and Zhi Lin. CPC classifications include C07K 1/13 and G01N 33/582. Patent application publications are informational records and do not constitute a granted patent or enforceable IP rights at this stage.

Anti-CRISPR Polypeptide Delivery for Cell Cytosol

USPTO published patent application US20260109737A1 on April 23, 2026, covering engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and/or nucleus of cells. The application names five inventors: Amit Choudhary, Axel O. Vera, Bradley Pentelute, Nicholas Truex, and Ronald T. Raines, with a filing date of August 20, 2025 and application number 19304906. CPC classifications span C07K 14/005, C07K 14/32, C07K 14/34, and related subclasses covering peptide and nucleic acid delivery technologies.

Tri-Segmented Pichinde Viruses as Vaccine Vectors

Hookipa Biotech GmbH has filed USPTO patent application US20260109736A1, published April 23, 2026, covering tri-segmented Pichinde viruses engineered with rearranged open reading frames (ORFs) in their genomes as vaccine vectors. The application claims virus particles comprising one L segment and two S segments or two L segments and one S segment, suitable for vaccines and immunotherapies. The filing date is June 6, 2025.

Octapeptide Patent Filed for Antibacterial

USPTO published patent application US20260109735A1 for an immunomodulatory octapeptide with broad-spectrum antibacterial activity, filed September 2, 2025 under Application No. 19317121. The application names Feiyun Yang, Jinxiu Huang, and Xiuliang Ding as inventors and covers the peptide's preparation method, purity testing, and applications in anti-bacterial and immunomodulation fields for animal husbandry. CPC classifications include C07K 7/64, A61P 31/04, C12P 21/02, G01N 33/6851, and A61K 38/00.

Novel Protein A Ligands Enable Milder Elution pH for Affinity Chromatography

Technische Universität München has filed US Patent Application US20260109738A1 for novel Staphylococcal Protein A ligands for affinity chromatography. The application covers two mutated ligand constructs — a single mutant Z(H18S)4 (histidine-to-serine substitution) and a double mutant Z(H18S, N28A)4 (histidine-to-serine and asparagine-to-alanine substitutions) — compared against the unmutated Z4 sequence used in commercial Protein A stationary phases. Testing reportedly demonstrated a >0.5 pH unit reduction in elution pH and a >30% yield improvement at pH 4.0 step-wise elution for the double mutant versus the wild-type ligand, with no decrease in dynamic binding capacity. The application was filed on October 21, 2025, and published on April 23, 2026.

Methods and Compositions for Hematopoietic Cell Differentiation

USPTO published application US20260109951A1 titled "Methods and Compositions for Inducing Hematopoietic Cell Differentiation," filed September 12, 2023. The application discloses culture platforms, cell media, and methods for differentiating pluripotent stem cells into hematopoietic lineage cells including T cell progenitors, NK cells, NKT cells, and B cells. Named inventors are Alec Witty, Amanda Yzaguirre, Jode Goodridge, Bahram Valamehr, Samuel Adam LaBarge, and Sean Sherman.

Particle-Based Separation of Extracellular Vesicles, University of Idaho, Apr 23, 2026

The University of Idaho has published patent application US20260109943A1, covering methods, compositions, and kits for isolating extracellular vesicles (EVs) using a chitin-based stationary phase material functionalized with a fusion protein comprising a lactadherin C1C2 domain, a chitin-binding domain (CBD), and an intein. The application, filed October 17, 2025, was published April 23, 2026. CPC classifications include C12N 5/04, C07K 14/46, and C07K 2319/00. Inventors are listed as Ching-An Peng.

T-Cell Modulatory Polypeptides and KRAS Peptide Cancer Treatment Methods

USPTO published patent application US20260109958A1 by inventors Chee Meng Low and Ahmet Selim Vakkasoglu on April 23, 2026, covering T-cell modulatory polypeptides (TMPs) comprising a KRAS peptide linked to class I MHC polypeptides, fusion molecules with heterologous partners, and single-chain immunomodulatory constructs with Ig Fc or non-Ig scaffolds. The application claims compositions and methods for modulating T-cell activity and treating KRAS-associated cancers including lung, colorectal, and pancreatic cancers. Filing date was December 16, 2025, under application number 19422115.

Anti-HER2 Antibodies and Methods of Use Thereof

The USPTO published patent application US20260109781A1 for anti-HER2 antibodies on April 23, 2026, filed October 8, 2025 under application number 19352786. The application covers antibodies binding to subdomain II and/or subdomain IV of human HER2, including bispecific formats using a common light chain, for treating cancer and brain metastasis. Inventors include Abira Bandyopadhyay, Allisa Jayne Clemens, Do Jin Kim, Michelle E. Pizzo, Lu Shan, Richard Théolis Jr., and Raymond Ka Hang Tong.

Harpoon Therapeutics Trispecific Protein BCMA Patent Application

Harpoon Therapeutics, Inc. filed patent application US20260109773A1 covering B cell maturation agent (BCMA) targeting trispecific proteins. The disclosed proteins comprise a CD3 binding domain, a half-life extension domain, and a BCMA binding domain, along with pharmaceutical compositions, nucleic acids, and methods of use for treating diseases and disorders. Application No. 19249844 was filed June 25, 2025, with inventors Holger Wesche, Bryan D. Lemon, and Richard J. Austin listed.

Chugai Seiyaku Bispecific Antibody Substitutes Coagulation Factor VIII

Chugai Seiyaku Kabushiki Kaisha filed patent application US20260109782A1 for bispecific antibodies that specifically bind to both Factor IX/Factor IXa and Factor X, functionally substituting for blood coagulation Factor VIIIa. The disclosed antibody A44/B26 reduced coagulation time by 50 seconds or more compared to untreated controls. The inventors further developed commonly shared light-chain antibodies using the L chain from antibody A44, demonstrating that A44L can serve as shared L chains for multispecific antibody constructs with appropriate CDR shuffling.

Selective Targeting of Host CD70+ Alloreactive Cells to Prolong Allogeneic CAR T Cell Persistence

Allogene Therapeutics, Inc. filed USPTO Patent Application US20260109771A1, published April 23, 2026, covering CD70-binding proteins, engineered immune cells (CAR-T cells), and methods for treating cancer including solid tumors and hematologic tumors. The application also claims engineered cells expressing both a CD70 CAR and a second CAR targeting a cancer-characteristic molecule, with optional reduction of TRAC, CD52, or CD70 expression. The filing date was December 15, 2025.

Formulations With Reduced Degradation of Polysorbate, Genentech

USPTO published patent application US20260108611A1 assigned to Genentech, Inc. on April 23, 2026, with a filing date of December 18, 2025. The application covers aqueous pharmaceutical formulations comprising a polypeptide, polysorbate, and cyclodextrin designed to reduce polysorbate degradation and decrease visible and sub-visible particle formation. Inventors are Brian ConnOLLY, Lydia Hamburg, and Emily Holz.

Monovalent CD47 Binding Proteins - Caedo Oncology, Apr 23, 2026

Caedo Oncology AS has published patent application US20260109764A1 for monovalent CD47 binding proteins and antibodies for therapeutic use. The application, filed October 9, 2023, claims binding proteins with one antigen binding domain targeting specific amino acid residues (Q19, N45, T120, R121, E122, G123) within CD47 as defined by SEQ ID NO:19. The inventors are Kjetil Hestdal, Rolf Dagfinn Pettersen, Nina Richartz, Sittana Matar, and Seham Skah. This publication makes the application available for public inspection and potential prior art challenges.

Anti-PiLRA Antibodies, Uses Thereof, and Related Methods and Reagents

Denali Therapeutics Inc. filed patent application 18714069 on December 16, 2022, published as US20260109763A1 on April 23, 2026, covering anti-PILRA antibodies with selectivity profiles allowing comparable binding to cynomolgus and human PILRA proteins while exhibiting much weaker binding to human PILRB protein. The antibodies bind both PILRA G78 and R78 variants and may be used in animal studies without surrogate molecules and for treating subjects with either PILRA variant. This is a standard USPTO patent application publication and does not create compliance obligations.

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR SOLID TUMORS

Amgen Inc. filed patent application US20260109776A1 covering human agonistic CD40 multispecific antibody constructs engineered to target the CD40 pathway on tumor-associated APCs for the treatment of solid tumors without systemic CD40 activation. The application was published on April 23, 2026 with filing date December 16, 2025 and application number 19421479, naming six inventors including Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, and Deepali Sawant. CPC classifications span C07K 16 antibody constructs and A61P 35/04 for antineoplastic agents.

Merck Stable PD-1 Antibody Formulations 5-250 mg/mL Pembrolizumab Cancer Treatment

Merck Sharp & Dohme LLC filed USPTO Application US20260109768A1 on April 23, 2026, covering stable formulations of anti-PD-1 antibodies (5-250 mg/mL concentration range) with buffer, stabilizer, surfactant, and antioxidant excipients, specifically identifying pembrolizumab as the target antibody. The application names William P. Forrest Jr., Chakravarthy Nachu Narasimhan, and Yogita Krishnamachari as inventors and claims methods for treating various cancers via intravenous or subcutaneous administration. Patent prosecution will determine scope and grant likelihood.

University of California Files Tumor-Neoantigen Antibody Patents for Cancer

The Regents of the University of California filed patent application US20260109786A1 on April 23, 2026, covering chemically controlled monoclonal antibodies reactive with tumor-specific neoantigens and neoantigen-binding fragments. The application also discloses related nucleic acids, expression cassettes, and expression vectors encoding the antibodies. Inventors include Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, and Peter J. ROHWEDER. The antibodies and fragments are disclosed as useful for cancer diagnosis and treatment.

Cell-Free Vascular Grafts and Graft Materials for Cellular Recruitment

USPTO published patent application US20260097149A1 for cell-free vascular graft materials incorporating bispecific binding partners with luminal and cellular binding domains for cellular recruitment. The application, filed June 26, 2023 under Application No. 18880781, covers fusion peptides with heparin and monocyte binding domains, methods of making the grafts, and methods of use including A-TEV technology.

Method for Treating Neurodegenerative Diseases with Polymer-Flavonoid Conjugates

The USPTO published patent application US20260097130A1 for a method of treating neurodegenerative diseases using polymer-flavonoid conjugates. Inventors Chun-Ting Cheng, Kuo-Liang Hou, and Pauline Ying Lau claim compositions that enable therapeutic materials to cross the blood-brain barrier. The application covers treatment of Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease using the disclosed nanocomplex formulations.

Solanum Lycopersicum Plants Having Improved Tobamovirus Resistance

The USPTO published patent application US20260096533A1 granting protection for hybrid Solanum lycopersicum tomato plants containing the Rug-1 resistance gene that confers Tomato Brown Rugose Fruit Virus (ToBRFV) tolerance/resistance. The patent covers the plant, seeds, fruits, plant parts, and methods for identifying, selecting, and producing ToBRFV-resistant tomato plants using the specified genetic marker.

Implantable Device for Administering a Therapeutic Agent

USPTO published patent application US20260096984A1 filed by inventors Harsh Patel and Jeffrey Haley on October 3, 2025. The application covers an implantable device for delivering therapeutic agents, featuring a core polymer matrix with hydrophobic poly ortho ester (POE) polymer having a glass transition temperature between -20°C and 40°C. The device is designed for controlled therapeutic agent release in vivo.

Antibody-Drug Conjugate Targeting GRP94 for Cancer Treatment

The USPTO published patent application US20260097129A1 for an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 (glucose-regulated protein 94) or an antigen-binding fragment thereof. The invention includes a pharmaceutical composition for treating cancer, leveraging strong internalization activity against GRP94-overexpressed carcinomas. The conjugate effectively inhibits growth of cetuximab-resistant colorectal cancer cell lines including HT29, HCT116, HCT8, and LoVo cells.

Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof

The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.

Protein Purification Using Chemically Activated Carbon at 0.1-15 wt%

USPTO published patent application US20260098056A1 for a method of purifying proteins from fermentation-derived solutions using chemically activated carbon. The method involves contacting the solution with 0.1-15 wt% activated carbon at pH 4-12 and temperature 2-60°C. Inventors: Sebastian Schoof, Thomas Kaeding, Gabriele Iffland. Application filed October 6, 2025.

Mammalian Cell SHMT2 Reduction for Protein Production

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.

AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks

USPTO published patent application US20260098085A1 titled 'Methods for Treating Age-Related Macular Degeneration.' The application covers methods for reducing treatment burden for patients with intraocular neovascular disorders by administering VEGF antagonists on 8-week and/or 12-week dosing schedules. Inventors include Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, and Andreas Weichselberger. The application was filed on June 25, 2025.

IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases

USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.

Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics

The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.

Protein Crystallization Method, Multiple Protein Feeds

Protein Crystallization Method, Multiple Protein Feeds

High-Purity Recombinant Human Albumin Preparation Method

Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.

Modified Protein Scaffold Patent by Evolveritas

The USPTO published patent application US20260098080A1 for a modified protein scaffold comprising amino acid sequence SEQ ID NO: 115 with specific amino acid modifications in defined positions. The application was filed by Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság, a Hungarian biotechnology company, with eight named inventors. The claimed protein scaffold includes segment formula Ih-mod GX1CX1VX2X3X4X5 and is intended for pharmaceutical preparations, kits, and screening procedures.

Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV

The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.

Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1

USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.

CD7 Antibody Antagonists for Therapeutic Applications

USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.

HIV/HBV Treatment Using CD8-Targeting Fusion Proteins

USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.

Cμ4 Region for Multi-Specific Antibody Chain Pairing

USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.